Drawing for NUOPTII

USPTO serial 87650626

NUOPTII

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
SIRIGNANO, EMMA MARIE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NUOPTII?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Claudia A. Smith

Claudia A. Smith WHITE & CASE LLP1221 AVENUE OF THE AMERICASTRADEMARK DEPARTMENTNEW YORK, NY 10020

Goods and services

ClassDescriptionStatusFirst use
005Vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy; pharmaceutical preparations and substances for the prevention and treatment of Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; diagnostic agents, reagents, preparations and substances for medical purposesABANDONED—
010Medical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; injection devices for pharmaceuticals, syringes and needles for injections and medical purposes; integrated medical systems, namely, medical diagnostic imaging apparatus and software sold as a unit therewith for managing, measuring, monitoring, assessing, controlling, collecting, storing and examining patient and client data and information captured by the medical system in web-based physical, psychological and neurological examinations conducted at a distance and at a clinic; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systemsABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 8, 2021MAB5ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION—
Jun 8, 2021ABN5ABANDONMENT - AFTER PUBLICATION—
Jun 7, 2021EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Jan 6, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 5, 2021EX5GSOU EXTENSION 5 GRANTED—
Dec 21, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 4, 2020EXT5SOU EXTENSION 5 FILED—
Dec 4, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 5, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 3, 2020EX4GSOU EXTENSION 4 GRANTED—
Jun 3, 2020EXT4SOU EXTENSION 4 FILED—
Jun 3, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 5, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 3, 2019EX3GSOU EXTENSION 3 GRANTED—
Dec 3, 2019EXT3SOU EXTENSION 3 FILED—
Dec 3, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 4, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 31, 2019EX2GSOU EXTENSION 2 GRANTED—
May 31, 2019EXT2SOU EXTENSION 2 FILED—
May 31, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 8, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 6, 2018EX1GSOU EXTENSION 1 GRANTED—
Dec 6, 2018EXT1SOU EXTENSION 1 FILED—
Dec 6, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 26, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 1, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 1, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 11, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 23, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 23, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Mar 23, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 23, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 23, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 1, 2018GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Feb 1, 2018GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Feb 1, 2018CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jan 31, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jan 26, 2018DOCKASSIGNED TO EXAMINER—
Oct 27, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 21, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance